Leah Lawrence
Abstract
Panobinostat added to bortezomib/dexamethasone for treating relapsed/refractory multiple myeloma improved progression-free survival and complete response rates.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Panobinostat added to bortezomib/dexamethasone for treating relapsed/refractory multiple myeloma improved progression-free survival and complete response rates.
Key concepts: Refractory (planetary science), Multiple myeloma, Medicine, Carfilzomib, Drug, Oncology, Internal medicine, Lenalidomide